Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc2.4 | Diabetes 1 | ECE2019

Empagliflozin attenuates the progression of atherosclerosis in APO-E knockout mice

Dimitriadis Georgios K , Nasiri-Ansari Narjes , Agrogannis Georgios , Nikiteas Nikolaos , Kostakis Ioannis D , Kaltsas Gregory , Papavassiliou Athanasios G , Kassi Eva , Randeva Harpal S

Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...